Análisis Argos
CNC
CNCBarata · ojo al riesgo
Centene Corp. · Healthcare
US$ 64.02
precio al 2026-07-28
Valor justo Argos*
US$ 110–119
vs. su valor justo
46% por debajo
Score Argos
66/100
Barata · ojo al riesgo
LA RESPUESTA
El mercado la precia para que se encoja 17.7% al año — menos de lo que viene demostrando (2.4%). Un negocio de calidad castigado por expectativas pesimistas: por eso está entre las llamadas de Argos. Ojo: tiene señales de riesgo en sus números — es barata con asterisco.
Recompensas
Cotiza por debajo de su valor justo: el mercado le pide menos crecimiento del que viene demostrando.
Riesgos
!Venta significativa de insiders en el último trimestre.
!Balance frágil: la deuda pesa sobre el negocio.
VALOR4/6FUTURO3/6PASADO2/6SALUD1/6DIVIDENDO2/6
El Iris de calidad
VALOR4/6FUTURO3/6PASADO2/6SALUD1/6DIVIDENDO2/6
ValorCotiza por debajo de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance frágil
DividendoRetorno al accionista moderado
Score Argos66de 100Barata · ojo al riesgo
Ingresos19%
US$ 194.8 B
Margen operativo305%
-3.9%
Flujo de caja libre982%
US$ 4.3 B
Deuda neta
US$ 0.9 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 31.6B
P/E
EV/EBITDA
FCF yield13.7%
ROIC-36.3%
Margen operativo-3.9%
Crecim. ingresos+19.4%/año
Piotroski F6/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 10 jul
Centene's Illinois Medicaid Renewal: A Win for Long-Term Growth?
Centene secures a four-year Illinois Medicaid contract renewal, preserving a key membership base and reinforcing long-term revenue stability.
prnewswire.com · 10 jul
CENTENE CORPORATION TO HOST 2026 SECOND QUARTER FINANCIAL RESULTS EARNINGS CALL
ST. LOUIS, July 10, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, shared today that it will release its 2026 second quarter financial results at approximately 6:00 a.m. ET on Tuesday, July 28, 2026, and host a conference call at 8:30 a.m.
zacks.com · 9 jul
Can Centene's Operational Execution Keep Margin Recovery on Track?
Centene Corporation's CNC margin recovery story appears to be shifting from strategy to execution. The company has rolled out several initiatives to better manage medical costs, modernize and standardize processes, and strengthen payment integrity.
prnewswire.com · 9 jul
CENTENE SUBSIDIARY MERIDIAN HEALTH PLAN OF ILLINOIS AWARDED ILLINOIS MEDICAID CONTRACT
ST. LOUIS, July 9, 2026 /PRNewswire/ -- Centene Corporation (Centene) (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its Illinois subsidiary, Meridian Health Plan of Illinois, Inc. (Meridian), has been selected by the Illinois Department of Healthcare and Family Services (HFS) to continue providing services for the HealthChoice Illinois Medicaid managed care program. The four-year contract is expected to begin January 1, 2027, through 2030.
zacks.com · 6 jul
Can Centene's Fraud Prevention Strategy Support Margin Recovery?
CNC expands AI-driven fraud prevention and payment integrity to improve Medicaid margins, boost cost controls and support long-term earnings growth.
seekingalpha.com · 6 jul
Centene: How Paperwork Disrupted An Entire Sector
Centene offers a defensive shelter as the AI infrastructure market faces skepticism and volatility. ACA insurance exchanges suffered adverse selection as healthy individuals exited, leaving a sicker, costlier pool. Regulatory shifts and flawed industry algorithms led to unexpected losses for insurers unable to adjust patient mix.
zacks.com · 2 jul
Can Centene's Integrated Healthcare Model Support Earnings Growth?
CNC's integrated healthcare model, AI-driven operations and improving Medicaid margins are strengthening earnings as the company raises 2026 EPS guidance.
zacks.com · 29 jun
Best Growth Stocks to Buy for June 29th
CLS, CBOE, and CNC it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 29, 2026.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.